Singapore markets closed

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.9767+0.0783 (+8.72%)
At close: 04:00PM EDT
0.9839 +0.01 (+0.74%)
After hours: 07:41PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
60,281
60,281
27,148
6,149
3,958
Operating expenses
Research development
126,509
126,509
127,726
111,090
91,568
Selling general and administrative
71,810
71,810
61,090
57,305
45,795
Total operating expenses
198,319
198,319
188,816
168,395
137,363
Operating income or loss
-138,038
-138,038
-161,668
-162,246
-133,405
Total other income/expenses net
19,539
19,539
-2,833
3,852
1,162
Income before tax
-112,535
-112,535
-162,959
-157,299
-129,930
Income tax expense
1,336
1,336
2,497
791
162
Income from continuing operations
-113,871
-113,871
-165,456
-158,090
-130,092
Net income
-113,871
-113,871
-165,456
-158,090
-130,092
Net income available to common shareholders
-113,871
-113,871
-165,456
-158,090
-130,092
Basic EPS
-0.54
-0.54
-1.02
-1.02
-0.90
Diluted EPS
-0.54
-0.54
-1.02
-1.02
-0.90
Basic average shares
185,262
201,073
161,207
155,806
142,464
Diluted average shares
185,262
201,073
161,207
155,806
142,464